Romosozumab-话题@MedSci - 梅斯（MedSci）

#Romosozumab#

10篇内容 | 1091人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1519078, encodeId=2fd415190e8b9, content=<a href='/topic/show?id=47af156202e' target=_blank style='color:#2F92EE;'>#Romosozumab#</a>, objectTitle=J Bone Miner Res：骨形成剂Romosozumab单抗治疗效果研究, objectType=article, longId=726779, objectId=e9a2e267798f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e9a2e267798f, replyNumber=0, likeNumber=63, createdTime=2022-05-14, rootId=0, userName=shuangle, userId=a01311239427, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e9a2e267798f, moduleTitle=J Bone Miner Res：骨形成剂Romosozumab单抗治疗效果研究, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=e9a2e267798f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1519077, encodeId=5e6e15190e70a, content=<a href='/topic/show?id=47af156202e' target=_blank style='color:#2F92EE;'>#Romosozumab#</a>, objectTitle=骨质疏松症新药Evenity（romosozumab）获多国批准上市，中国临床试验也已开展, objectType=article, longId=195358, objectId=54c419535853, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=54c419535853, replyNumber=0, likeNumber=74, createdTime=2020-06-07, rootId=0, userName=shuangle, userId=a01311239427, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=54c419535853, moduleTitle=骨质疏松症新药Evenity（romosozumab）获多国批准上市，中国临床试验也已开展, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=54c419535853)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1519076, encodeId=3a7715190e621, content=<a href='/topic/show?id=47af156202e' target=_blank style='color:#2F92EE;'>#Romosozumab#</a>, objectTitle=欧盟批准将Evenity（romosozumab）用于治疗绝经后妇女的骨质疏松症, objectType=article, longId=184834, objectId=6c4b184834d0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6c4b184834d0, replyNumber=0, likeNumber=75, createdTime=2019-12-18, rootId=0, userName=shuangle, userId=a01311239427, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6c4b184834d0, moduleTitle=欧盟批准将Evenity（romosozumab）用于治疗绝经后妇女的骨质疏松症, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6c4b184834d0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1519075, encodeId=026415190e57e, content=<a href='/topic/show?id=47af156202e' target=_blank style='color:#2F92EE;'>#Romosozumab#</a>, objectTitle=安进和优时比的骨质疏松药物Evenity（romosozumab）喜获欧洲药品管理局推荐, objectType=article, longId=181603, objectId=223b18160372, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=223b18160372, replyNumber=0, likeNumber=81, createdTime=2019-10-21, rootId=0, userName=shuangle, userId=a01311239427, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=223b18160372, moduleTitle=安进和优时比的骨质疏松药物Evenity（romosozumab）喜获欧洲药品管理局推荐, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=223b18160372)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1519074, encodeId=61a015190e462, content=<a href='/topic/show?id=47af156202e' target=_blank style='color:#2F92EE;'>#Romosozumab#</a>, objectTitle=安进/优时比的抗骨硬化蛋白单抗romosozumab，获FDA批准治疗绝经后妇女的骨质疏松症, objectType=article, longId=164049, objectId=df2216404974, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=df2216404974, replyNumber=0, likeNumber=66, createdTime=2019-04-12, rootId=0, userName=shuangle, userId=a01311239427, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=df2216404974, moduleTitle=安进/优时比的抗骨硬化蛋白单抗romosozumab，获FDA批准治疗绝经后妇女的骨质疏松症, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=df2216404974)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1519073, encodeId=00bd15190e3f8, content=<a href='/topic/show?id=47af156202e' target=_blank style='color:#2F92EE;'>#Romosozumab#</a>, objectTitle=EMA接受了Romosozumab治疗骨质疏松症的上市授权申请, objectType=article, longId=128300, objectId=0d7d12830097, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0d7d12830097, replyNumber=0, likeNumber=103, createdTime=2018-02-01, rootId=0, userName=shuangle, userId=a01311239427, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0d7d12830097, moduleTitle=EMA接受了Romosozumab治疗骨质疏松症的上市授权申请, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=0d7d12830097)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1519072, encodeId=d2e715190e25d, content=<a href='/topic/show?id=47af156202e' target=_blank style='color:#2F92EE;'>#Romosozumab#</a>, objectTitle=NEJM：Romosozumab用于绝经后女性骨折的预防, objectType=article, longId=115967, objectId=6ebc11596e10, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6ebc11596e10, replyNumber=0, likeNumber=79, createdTime=2017-10-14, rootId=0, userName=shuangle, userId=a01311239427, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6ebc11596e10, moduleTitle=NEJM：Romosozumab用于绝经后女性骨折的预防, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=6ebc11596e10)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1519071, encodeId=6a3115190e18c, content=<a href='/topic/show?id=47af156202e' target=_blank style='color:#2F92EE;'>#Romosozumab#</a>, objectTitle=安进在日本提交骨质疏松症新药romosozumab上市申请，治疗男性和女性骨质疏松症, objectType=article, longId=85433, objectId=b5378543352, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b5378543352, replyNumber=0, likeNumber=93, createdTime=2016-12-26, rootId=0, userName=shuangle, userId=a01311239427, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b5378543352, moduleTitle=安进在日本提交骨质疏松症新药romosozumab上市申请，治疗男性和女性骨质疏松症, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=b5378543352)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1519070, encodeId=1a2c15190e00e, content=<a href='/topic/show?id=47af156202e' target=_blank style='color:#2F92EE;'>#Romosozumab#</a>, objectTitle=NEJM：绝经后女性骨质疏松，Romosozumab可显著降低骨折风险, objectType=article, longId=78056, objectId=59ffe805698, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59ffe805698, replyNumber=0, likeNumber=67, createdTime=2016-09-22, rootId=0, userName=shuangle, userId=a01311239427, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59ffe805698, moduleTitle=NEJM：绝经后女性骨质疏松，Romosozumab可显著降低骨折风险, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=59ffe805698)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1519069, encodeId=13f8151906976, content=<a href='/topic/show?id=47af156202e' target=_blank style='color:#2F92EE;'>#Romosozumab#</a>, objectTitle=NEJM：Romosozumab治疗绝经后女性骨质疏松症优于特立帕肽, objectType=article, longId=36898, objectId=8a9e36898ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a9e36898ad, replyNumber=0, likeNumber=63, createdTime=2014-06-25, rootId=0, userName=shuangle, userId=a01311239427, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a9e36898ad, moduleTitle=NEJM：Romosozumab治疗绝经后女性骨质疏松症优于特立帕肽, moduleType=article, hrefUrl=//m.capotfarm.com/article/show_article.do?id=8a9e36898ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Romosozumab

2020-05-29

shuangle (审核中...)

前往app查看评论内容

#Romosozumab#

J Bone Miner Res：骨形成剂Romosozumab单抗治疗效果研究

2022-05-14

shuangle (审核中...)

前往app查看评论内容

#Romosozumab#

骨质疏松症新药Evenity（romosozumab）获多国批准上市，中国临床试验也已开展

2020-06-07

shuangle (审核中...)

前往app查看评论内容

#Romosozumab#

欧盟批准将Evenity（romosozumab）用于治疗绝经后妇女的骨质疏松症

2019-12-18

shuangle (审核中...)

前往app查看评论内容

#Romosozumab#

安进和优时比的骨质疏松药物Evenity（romosozumab）喜获欧洲药品管理局推荐

2019-10-21

shuangle (审核中...)

前往app查看评论内容

#Romosozumab#

安进/优时比的抗骨硬化蛋白单抗romosozumab，获FDA批准治疗绝经后妇女的骨质疏松症

2019-04-12

shuangle (审核中...)

前往app查看评论内容

#Romosozumab#

EMA接受了Romosozumab治疗骨质疏松症的上市授权申请

2018-02-01

shuangle (审核中...)

前往app查看评论内容

#Romosozumab#

NEJM：Romosozumab用于绝经后女性骨折的预防

2017-10-14

shuangle (审核中...)

前往app查看评论内容

#Romosozumab#

安进在日本提交骨质疏松症新药romosozumab上市申请，治疗男性和女性骨质疏松症

2016-12-26

shuangle (审核中...)

前往app查看评论内容

#Romosozumab#

NEJM：绝经后女性骨质疏松，Romosozumab可显著降低骨折风险

2016-09-22

shuangle (审核中...)

前往app查看评论内容

#Romosozumab#

NEJM：Romosozumab治疗绝经后女性骨质疏松症优于特立帕肽

2014-06-25

科室
- - 订阅+
  - 更多科室
工具
服务